Opaleye Management’s Trevi Therapeutics TRVI Stock Holding History

Opaleye Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.78M	Sell	310,000 -35,100	-10%	-$510K	0.52%	33
2026 Q1	$4.12M	Hold	345,100	–	–	0.54%	35
2025 Q4	$4.32M	Sell	345,100 -44,900	-12%	-$519K	0.57%	35
2025 Q3	$3.57M	Hold	390,000	–	–	0.5%	31
2025 Q2	$2.13M	Sell	390,000 -405,000	-51%	-$2.52M	0.43%	34
2025 Q1	$5M	Sell	795,000 -1,522,500	-66%	-$7.26M	1.11%	18
2024 Q4	$9.55M	Sell	2,317,500 -250,490	-10%	-$802K	1.67%	14
2024 Q3	$8.58M	Sell	2,567,990 -77,010	-3%	-$229K	1.43%	17
2024 Q2	$7.88M	Hold	2,645,000	–	–	1.8%	15
2024 Q1	$9.13M	Buy	2,645,000 +110,000	+4%	+$245K	1.99%	18
2023 Q4	$3.4M	Buy	2,535,000 +829,100	+49%	+$1.26M	0.9%	27
2023 Q3	$3.72M	Buy	1,705,900 +4,400	+0.3%	+$9.94K	1.21%	24
2023 Q2	$4.07M	Buy	1,701,500 +865,700	+104%	+$2.18M	0.97%	27
2023 Q1	$1.55M	Buy	835,800 +350,800	+72%	+$794K	0.46%	38
2022 Q4	$936K	Buy	+485,000	New	+$956K	0.33%	39

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Opaleye Management's TRVI Position: Q2 2026 in Review

Opaleye Management reduced its Trevi Therapeutics (TRVI) stake by 10% in Q2 2026, selling an estimated $510K and leaving 310,000 shares worth $5.78M. The position accounts for 0.52% of the portfolio, ranked #33.

Opaleye Management first reported a position in TRVI in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.55M in Q4 2024. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Opaleye Management held 310,000 shares of Trevi Therapeutics worth $5.78M as of Q2 2026.
Opaleye Management sold 35,100 Trevi Therapeutics shares in Q2 2026, an estimated $510K.
Trevi Therapeutics made up 0.52% of Opaleye Management's portfolio in Q2 2026, its #33 holding.
Opaleye Management first reported a position in Trevi Therapeutics in Q4 2022 and has held it in 15 quarters since.
Opaleye Management's Trevi Therapeutics position peaked at $9.55M in Q4 2024.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.